Memo Therapeutics AG has entered into a collaboration and option agreement with CSL to advance the development of its recombinant polyclonal IgG technology. The agreement includes funding from CSL to support exploratory research and development activities.
This partnership aims to leverage Memo Therapeutics’ expertise in recombinant antibody technology alongside CSL’s resources to accelerate the progress of novel therapeutic candidates.
**Why this matters**
The collaboration could enhance the development of new antibody-based treatments by combining recombinant polyclonal IgG technology with CSL’s capabilities. This approach has the potential to improve the efficacy and diversity of antibody therapies for various diseases.
Source: NewsData